34. 神経線維腫症 Neurofibromatosis Clinical trials / Disease details
臨床試験数 : 137 / 薬物数 : 213 - (DrugBank : 76) / 標的遺伝子数 : 87 - 標的パスウェイ数 : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04481048 (ClinicalTrials.gov) | December 15, 2020 | 15/5/2020 | Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 | Antioxidant Therapy With N-acetylcysteine for Motor Behavior and/or Learning in Children With Neurofibromatosis Type 1 | Neurofibromatosis 1 | Drug: N-Acetyl cysteine;Other: Placebo | Children's Hospital Medical Center, Cincinnati | United States Department of Defense | Recruiting | 8 Years | 16 Years | All | 58 | Phase 2 | United States |
| 2 | NCT04481035 (ClinicalTrials.gov) | January 15, 2019 | 14/4/2020 | Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 | Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 | Neurofibromatosis 1 | Drug: N-acetylcysteine (NAC);Other: Placebo | Children's Hospital Medical Center, Cincinnati | NULL | Active, not recruiting | 8 Years | 16 Years | All | 5 | Phase 2 | United States |